Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
The biologic drug is set to be used as a combination therapy for asthma.
Dupilumab (Dupixent) could be a long-term answer in reducing severe asthma exacerbations in both adults and adolescents with moderate-to-severe asthma.
Recently, investigators presented data from a 2200 phase 3 open-label extension trial during the European Respiratory Society (ERS) 2020 International Congress.
The trial represents the largest study of a biologic medicine ever conducted in asthma. The data shows the treatment promotes sustained improvements in lung function and asthma exacerbations across a broad patient population with type 2 inflammation, while maintaining a consistent safety profile for up to 3 years.
The data presented during the virtual conference includes information from 3 pivotal trials lasting between 24-52 weeks.
The open-label extension included patients who finished active treatment or placebo in the initial trials, with up to 2 years of additional treatment for 3 total years of treatment data available.
Overall, patients experienced improvement in lung function by 13-22% by 96 weeks, measured by the average change in forced expiratory volume over 1 second compared to baseline from the initial asthma trials.
There was also a low rate of severe asthma attacks with an average of 0.31-0.35 events per year.
In an interview with HCPLive®, Michael E. Wechsler, MD, MMSc, Director of the National Jewish Cohen Family Asthma Institute, explained the positive dupilumab results.